TREAT-NMD

From WikiProjectMed
Jump to navigation Jump to search

TREAT-NMD
Translational Research in Europe - Assessment and Treatment of Neuromuscular diseases
KeywordsNeuromuscular diseases, clinical research
Project typeNetwork of Excellence
Funding agencyEuropean Commission
ReferenceFP6-036825
ObjectiveImproving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research
Project coordinatorInstitute of Genetic Medicine, Newcastle University
ParticipantsUniversities, pharmaceutical companies, patient organisations
Websitewww.treat-nmd.org

TREAT-NMD (treat NeuroMuscular Disease) is a global academic network that focuses on advancing research in neuromuscular disorders.[1] It was established in 2007 with its coordination centre at the Newcastle University.[2] As of 2018, the network comprises over a hundred research centres and patient organisations from 54 countries[3] as well as independent academics and patient representatives.[4] The network's aim is to provide infrastructure to accelerating research through supporting collaboration between its members.[5] Its main goals include improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research.[6][7]

Through patient registries, TREAT-NMD provides genotype–phenotype correlation between genetic mutations and neuromuscular disease burden.[8]

References

  1. ^ Leary, Rebecca; Oyewole, Anne; Bushby, Katharine; Aartsma-Rus, Annemieke (6 July 2017). "Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD)". Neuropediatrics. 48 (4): 211–220. doi:10.1055/s-0037-1604110. PMID 28683502. S2CID 19283049.
  2. ^ Bushby, Katharine; Lynn, Stephen; Straub, Volker (July 2009). "Collaborating to bring new therapies to the patient--the TREAT-NMD model". Acta Myologica. 28 (1): 12–5. PMC 2859629. PMID 19772190.
  3. ^ "TREAT-NMD Alliance Members – Organizations". TREAT Neuromuscular Network. Retrieved 13 June 2018.
  4. ^ "TREAT-NMD Alliance Members – Individuals". TREAT Neuromuscular Network. Retrieved 13 June 2018.
  5. ^ "TREAT-NMD : About the TREAT-NMD network". TREAT Neuromuscular Network.
  6. ^ Willmann, Raffaella; Rüegg, Markus A.; Fairclough, Rebecca J.; Davies, Kay E; Possekel, Stefanie; Meier, Thomas (October 2008). "T.P.3.03 TREAT-NMD-Activity 7: Accelerate preclinical phase of new therapeutic treatment development". Neuromuscular Disorders (Conference abstract). 18 (9–10): 794. doi:10.1016/j.nmd.2008.06.242. S2CID 54330245.
  7. ^ Mercuri, Eugenio Maria; Mayhew, Anna G; Muntoni, Francesco; Straub, Volker; Van Ommen, Gert-Jan; Voit, Thomas; Bertini, Enrico; Bushby, Katherine (November 2008). "Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France". Neuromuscular Disorders (Workshop report). 18 (11): 894–903. doi:10.1016/j.nmd.2008.07.003. PMID 18818076.
  8. ^ Thompson R, Robertson A, Lochmüller H (2017). "Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease". Rare Diseases Epidemiology: Update and Overview. Advances in Experimental Medicine and Biology. Vol. 1031. pp. 97–124. doi:10.1007/978-3-319-67144-4_5. ISBN 978-3-319-67142-0. PMID 29214567.

Further reading

Retrieved from "https://mdwiki.org/wiki/TREAT-NMD"